Jade Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Jade Biosciences, Inc. (JBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $14.92 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2025-03-27
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $4.54.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $14.92, a 4.91% decline from fiscal 2023.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $15.69, a 49.71% increase from fiscal 2022.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $10.48, a 134.98% increase from fiscal 2021.
- Jade Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $4.46.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2024-12-31 | $14.92 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $14.92 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $14.92 10-Q · filed 2024-08-12 | |||
| 2023-12-31 | $15.69 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $16.06 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $16.28 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $10.48 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $10.05 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $8.73 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $4.54 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $4.46 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |